References
- Bai AP, Guo ZR, Hu WH, Shen F, Cheng GF. Design, synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3,4-diaryl-3-pyrrolin-2-ones. Chinese Chemical Letters 2001; 12: 775–778
- Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF. Imrecoxib: A novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacologica Sinica 2004; 25: 927–931
- Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: Getting to the heart of the matter. Journal of Pharmacy and Pharmaceutical Sciences 2004; 7: 332–336
- Dogne JM, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. Journal of Medicinal Chemistry 2005; 48: 2251–2257
- Donnelly MT, Hawkey CJ. Review article: COX-II inhibitors — a new generation of safer NSAIDS?. Alimentary Pharmacology Therapeutics 1997; 11: 227–236
- Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997; 53: 563–582
- Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, Geer LA, Halpin RA, Agrawal N, Rodrigues AD. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metabolism and Disposition 2001; 29: 813–820
- Lane NE. Pain management in osteoarthritis: The role of COX-2 inhibitors. Journal of Rheumatology 1997; 24: 20–24
- Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmcokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism and Disposition 2004; 32: 566–571
- Masferrer JL, Zweifel BS, Manning PT, Hauser DS, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proceedings of the National Academy of Sciences, USA, 1994; 91: 3228–3232
- Needleman P, Isakson PC. The discovery and function of COX-2. Journal of Rheumatology 1997; 24: 9–14
- Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: Two enzymes in the spotlight. Biochemical Pharmacology 2003; 65: 153–159
- Paulson SK, Hribar JD, Liu NWK, Hajdu E, Bible JRRH, Piergies A, Karim A. Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metabolism and Disposition 2000; 28: 308–314
- Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E, Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Canadian Journal of Physiology and Pharmacology 1997; 75: 1088–1095
- Shen F, Bai AP, Guo ZR, Cheng GF. Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages. Acta Pharmacologica Sinica 2002; 23: 762–768
- Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis and Rheumatism 1998; 41: 1591–1602
- Smith JM, Willis AL. Aspirin selectivity inhibitors prostaglandins production in human platelets. Nature: New Biology 1971; 231: 235–237
- Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Advances in Immunology 1996; 62: 167–215
- Thomas LG. Increased risk of cardiovascular events with coxibs and NSAIDs. Lancet 2005; 365: 1538–1539
- Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology 1971; 231: 232–235
- Yuan JJ, Yang DC, Zhang JY, Bible JRR, Karim A, Findlay JWA. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib in human. Drug Metabolism and Disposition 2002; 30: 1013–1021